Press releases - Ypsomed

Ypsomed concludes Licence Agreement on own autoinjector patents with Cilag GmbH International

09/18/2007 - 7:00am Press Releases Ypsomed Group

Burgdorf - Ypsomed is pleased to announce that it has granted to Cilag GmbH International, a non exclusive licence to use certain patents, which protect inventions of Ypsomed, for an autoinjector device for the administration of two biopharmaceutical products with an option to extend the licence for a number of other compounds. Ypsomed is not in a position to communicate the commercial details of the agreement, but expects to receive significant royalties over the term of the contract.

Change in responsibilities of production at Ypsomed

09/11/2007 - 7:00am Press Releases Ypsomed Group

Burgdorf - Ypsomed announces that Christoph Brand, Senior Vice President Production & Logistics and member of the Executive Management team leaves the company. Chief Operating Officer Maurice Meytre will take over this responsibility. With immediate effect Hansueli Lehmann as Head of the Solothurn Production site, Benjamin Reinmann as Head of the Burgdorf Production site und Ueli Bracher as Head of Logistics will report directly to Maurice Meytre.

Ypsomed files a breach of patent lawsuit against Sanofi-Aventis

08/27/2007 - 7:00am Press Releases Ypsomed Group

Burgdorf - Ypsomed filed a lawsuit against Sanofi-Aventis in Germany. Ypsomed believes that the SoloStar injection system developed and manufactured by Sanofi-Aventis is in breach of its own patents. Sanofi-Aventis uses the SoloStar pen for administration of its Lantus and Apidra insulin products.

Ypsomed takeover of Florian Müller Holding GmbH boosts diabetes direct business in Germany

08/07/2007 - 7:00am Press Releases Ypsomed Group

Burgdorf - With effect from 1 July 2007 and at a cost of around EUR 11 million (approx. CHF 18 million), Ypsomed has bought 100% of the shares in Florian Müller Holding GmbH, thus providing nationwide coverage in diabetes direct sales and distribution throughout Germany, with the focus on the care of insulin pump patients.

Ypsomed has a firm commitment to the region. From 27 June 2007 its shares will – in addition to the SWX – be listed on the Berne Exchange

06/26/2007 - 7:00am Press Releases Ypsomed Group

Burgdorf - Ypsomed Holding AGr ecently applied for a listing on the BX Berne eXchange in addition to the present listing on the SWX Swiss Exchange. The Berne Stock Market Association as the BX Berne eXchange operator has accepted this application. All the registered shares of Ypsomed Holding AG will therefore also be listed on the BX Berne eXchange from 27 June 2007.